Sanctuary Advisors LLC Sells 13,117 Shares of Kenvue Inc. (NYSE:KVUE)

Sanctuary Advisors LLC lowered its position in Kenvue Inc. (NYSE:KVUE) by 2.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 531,773 shares of the company’s stock after selling 13,117 shares during the period. Sanctuary Advisors LLC’s holdings in Kenvue were worth $11,550,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Leo Wealth LLC raised its position in shares of Kenvue by 0.3% in the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after acquiring an additional 481 shares in the last quarter. Alerus Financial NA raised its position in shares of Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC raised its position in shares of Kenvue by 1.9% in the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after acquiring an additional 500 shares in the last quarter. Principle Wealth Partners LLC raised its position in shares of Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after acquiring an additional 500 shares in the last quarter. Finally, White Pine Capital LLC grew its stake in shares of Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock worth $1,165,000 after buying an additional 542 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on KVUE. Citigroup cut their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Bank of America upped their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Canaccord Genuity Group cut their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus price target of $23.00.

Kenvue Stock Performance

Shares of KVUE opened at $22.00 on Wednesday. The business’s fifty day simple moving average is $21.30 and its two-hundred day simple moving average is $22.12. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a market cap of $42.17 billion, a price-to-earnings ratio of 41.50, a P/E/G ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Research analysts anticipate that Kenvue Inc. will post 1.05 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.73%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.